|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.95 - 3.16|
|52 Week Range||0.85 - 7.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Despite rapidly expanding its weed-growing capacity, this marijuana stock is at risk of being late to the party.
Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the fiscal quarter ended March 31, 2018. “Emerald has been very productive year-to-date in executing on three key strategic pillars: production scaling, product innovation, and branding,” said Chris Wagner, CEO of Emerald Health Therapeutics. “We received our cultivation license for our Pure Sunfarms joint venture, completed our first harvest and submitted an amendment to Health Canada for Pure Sunfarms’ sales license, and started commercial production.
Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has closed its prospectus sale (the “Offering”) to a single Canadian institutional accredited investor (the “Investor”) announced on May 15, 2018. Pursuant to the Offering, the Company has issued 4,000,000 units (the “Units”) at a price per Unit of $4.20 for gross proceeds of $16,800,000. Each Unit consists of one common share of the Company and one common share purchase warrant (a “Warrant”).
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Village Farms International Inc. (VFF.TO) (VFFIF) joint venture with Emerald Health Therapeutics Inc. (EMH.V) (EMHTF) called Pure Sunfarms. Village Farms, which has been publicly traded for more than ten years on the TSX, is already generating about CAD$200 million in annual revenue as a large-scale, low-cost greenhouse grower -- from its decades old fresh produce business. By leaning on this experience, the vertically-integrated company is now cultivating high-quality cannabis through Pure Sunfarms, which has the potential to produce up to 300,000 kilograms of dried cannabis per year if it converts all of its existing Delta, BC-based 4.8 million sq. ft. of greenhouse space to cannabis production.
VICTORIA, British Columbia, May 22, 2018-- Emerald Health Therapeutics, Inc. today announced that members of its executive team will present at upcoming investor conferences.. BMO Capital Market’ s Inaugural ...
Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 units of the Company (the “Units”) at a price of $4.20 per Unit for total gross proceeds of $16,800,000 (the “Offering”). The securities forming the Units will be qualified under a shelf prospectus supplement to be filed by Emerald prior to closing. Each Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”).
Though on track to be a major weed producer, this marijuana stock is far from a lock to succeed.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF), a British Columbia-based licensed producer that is checking all of the licensed producer boxes, building a diversified and vertically-integrated company that is poised to take full advantage of the legalization of cannabis. Long viewed as a science-oriented niche producer, the company is now in a position to be a major player in all aspects of the emergent industry. As adult-use legalization of cannabis approaches in Canada, anticipated this summer or perhaps early fall, the industry offers a wide array of companies looking to capitalize on this greatly expanded market.
Emerald Health Therapeutics, Inc. (“Emerald”) (EMH.V) (EMHTF) (TBD.F) announced today that it has acquired (the “Acquisition”) all of the issued and outstanding securities of 8611165 Canada Inc., an Access to Cannabis for Medical Purposes Regulations (ACMPR) Licensed Producer located in Saint-Eustache, Québec, and its affiliate 9353-8460 Québec Inc. (together, “Agro-Biotech”). Agro-Biotech’s assets include a Health Canada cultivation license, land, and 75,000 sq. ft. purpose-built facility. The Acquisition enhances this local startup’s resources to serve Québec consumers with high-quality cannabis products in the anticipated legalized adult-use market, and further strengthens Emerald’s ability to market throughout eastern Canada and nationwide.
Emerald Health Therapeutics, Inc. (“Emerald”) (EMH.V) (EMHTF) (TBD.F) has entered into a supply agreement with Pure Sunfarms, its 50/50 joint venture with Village Farms International Inc. (“Village Farms”) (VFF.TO) (VFFIF). Pure Sunfarms has substantially completed conversion of the first 250,000 ft2 of its existing 1.1 million ft2 greenhouse in Delta, BC (“Delta 3 greenhouse”) to cannabis production, with the balance of the 1.1 million ft2 expected to be completed by year end.
VICTORIA, British Columbia, April 20, 2018-- Emerald Health Therapeutics Inc. today announced DDB Canada’ s Vancouver office its agency of record following a national search managed by Reynolds & Fyshe. ...
New joint venture, Emerald Health Naturals, secures exclusive Canadian rights to sell proprietary non-cannabis health products that support the human endocannabinoid system. Initiative leverages natural ...
With major projects advancing, this burgeoning marijuana stock presents a mixed bag for investors.
VICTORIA, British Columbia, April 03, 2018-- Emerald Health Therapeutics Inc. has appointed Rebecca Wong as Vice President Quality Affairs, with responsibility for quality systems at Emerald’ s production ...
VICTORIA, British Columbia, April 02, 2018-- Emerald Health Therapeutics, Inc. has filed its audited financial statements and management discussion and analysis for the fiscal year ended December 31, 2017. ...